The prognosis of recurrent low-grade endometrial stromal sarcoma: a retrospective cohort study
Open Access
- 7 April 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Orphanet Journal of Rare Diseases
- Vol. 16 (1), 1-8
- https://doi.org/10.1186/s13023-021-01802-8
Abstract
The prognosis of recurrent low-grade endometrial stromal sarcoma (LGESS) is little known. This study was to investigate the survival outcomes of a cohort of patients with recurrent LGESS. Patients with primary LGESS diagnosed and treated for first recurrence confirmed by histology in the study center from February 2012 to June 2019 were retrospectively included. The progression-free interval (PFI) after the last treatment for first recurrence and overall survival (OS) since the diagnosis of first recurrence, which were followed up to June 1, 2020, were compared between groups of various therapy modalities. Fifty-six patients were included, and 43 patients (76.8%) had definite follow-up outcomes. The 5-year PFI and OS rates were 30.0% (95% confidence interval [95% CI] 29.2–30.8) and 75.0% (68.0–82.0), respectively. In univariate analysis, only fertility-sparing treatment, ovarian preservation and surgical treatment had a significant impact on the PFI (hazard ratio [HR] 4.5, 3.1, and 0.2; 95% CI 1.5–13.1, 1.3–7.3, and 0.1–0.7; and p = 0.006, 0.009 and 0.006, respectively), but no factor was found to be associated with increased mortality risk. After adjusted with hormone treatment or chemotherapy, surgical treatment had significant effectiveness on OS (HR 0.3 and 0.3, 95% CI 0.1–1.0 and 0.1–1.0, p = 0.045 and 0.049, respectively). None of the patients with fertility-sparing treatment had successful conception, and all experienced repeated relapse. For patients with recurrent LGESS, fertility-sparing treatment or ovarian preservation should not be provided. Surgery is the treatment of choice, and hormone treatment and/or chemotherapy was effective for the survival benefits of surgical treatment.Keywords
Funding Information
- CAMS Innovation Fund for Medical Sciences (CIFMS-2017-I2M-1-002)
This publication has 44 references indexed in Scilit:
- Can Proliferation Biomarkers Reliably Predict Recurrence in World Health Organization 2003 Defined Endometrial Stromal Sarcoma, Low Grade?PLOS ONE, 2013
- Stages I to II WHO 2003–Defined Low-Grade Endometrial Stromal Sarcoma: How Much Primary Therapy Is Needed and How Little Is Enough?International Journal of Gynecologic Cancer, 2013
- Prognostic indicators in WHO 2003 low‐grade endometrial stromal sarcomaHistopathology, 2013
- Long-term medroxyprogesterone acetate therapy for low-grade endometrial stromal sarcomaInternational Journal of Clinical Oncology, 2011
- Treatment of Recurrent or Metastatic Low-Grade Endometrial Stromal SarcomaInternational Journal of Gynecologic Cancer, 2010
- Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patientsHistopathology, 2009
- Lymphadenectomy and Ovarian Preservation in Low-Grade Endometrial Stromal SarcomaObstetrics & Gynecology, 2008
- Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: Single center experience with 10 cases and review of the literatureGynecologic Oncology, 2006
- Conservative management of a myxoid endometrial stromal sarcoma in a 16-year-old nulliparous womanGynecologic Oncology, 2005
- Prognostic Parameters in Endometrial Stromal Sarcoma: A Clinicopathologic Study in 31 PatientsGynecologic Oncology, 2001